Overview

Cycloserine rTMS Plasticity Augmentation in Depression

Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
0
Participant gender:
All
Summary
Transcranial magnetic stimulation (rTMS) is an investigational and therapeutic modality that impacts the connection strength between neurons by delivering patterned energy. In response to this patterned energy neurons fire and adapt by changing their connection strengths. This change in connection strengths is believed to be the underlying mechanism whereby this intervention has therapeutic benefit for this intervention in conditions such as depression. The purpose of this study is to test a means of enhancing the effect of rTMS using a medication (cycloserine) that has been shown to augment and stabilize activity dependent neuronal changes. The investigators wish to use the motor system, where the associated muscle response to brain stimulation can be measured, to probe activity dependent changes in connection strength between neurons.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Calgary
Treatments:
Cycloserine
Criteria
Inclusion Criteria:

1. Individuals currently experiencing a major depressive episode. 1.1 As determined by
the MINI-International Neuropsychiatric Interview 1.2 Moderate severity, as indicated
by a Hamilton Depression Rating Scale score of ≥15.

1.3 Be willing to remain on a stable medication regimen for 4 weeks prior the study
and during the study

2. Aged 18-60

Exclusion Criteria:

1. Pregnancy

2. Lactation

3. Epilepsy

4. Previous Stroke

5. Current Renal Disease

6. Current Liver Disease

7. Current Alcohol Use Disorder

8. Inability to refrain from alcohol use for 24 hours prior to each session and following
each session.

9. Allergy to antibiotics

10. Use of isoniazid, ethionamide, or bupropion

11. History of psychosis

12. History of bipolar disorder

13. Family history of bipolar disorder

14. Intracranial metallic objects (dental hardware is not an exclusionary criteria)